INTRODUCTION
============

*Pseudomonas aeruginosa*, an aerobic Gram-negative organism that is commonly discovered in soil, water, and plants, rarely causes illness in healthy people ([@B1]). However, *P. aeruginosa* sepsis often occurs in patients with burns, malignancies or immunodeficiency or in preterm infants ([@B1]). Most of these infections are nosocomially acquired ([@B1]). *P. aeruginosa* is a virulent organism that is susceptible to a limited number of antibiotic agents including antipseudomonal penicillins and cephalosporins, carbapenems, fluoroquinolones and ciprofloxacin ([@B2]-[@B4]). Despite recent improvements in therapy, *P. aeruginosa* bacteremia remains fatal in more than 20% of cases ([@B5]). In a recent large multicenter study of all age groups, *P. aeruginosa* bloodstream infection (BSI) was associated with crude mortality rates of 39% in all patients and 48% in intensive care unit patients ([@B6]).

The outcome of *P. aeruginosa* bacteremia has been shown to be related to microbial ([@B7], [@B8]) and host factors ([@B9]-[@B11]) and treatment ([@B10]-[@B12]). Understanding these factors may provide an improvement in treatment outcome.

Despite an abundance of studies on the risk factors for multi-drug resistance (MDR) and mortality of *P. aeruginosa* bacteremia, relatively few studies on *P. aeruginosa* bacteremia in children have been reported in recent years ([@B13]-[@B16]). We conducted an analysis of 62 pediatric patients with *P. aeruginosa* bacteremia at a tertiary care children\'s hospital during a recent ten-year period. We investigated the risk factors for acquisition of MDR *P. aeruginosa* and the mortality rate associated with *P. aeruginosa* bacteremia as well as its clinical characteristics and antibiotic susceptibility.

MATERIALS AND METHODS
=====================

This was a retrospective analysis conducted at the Seoul National University Children\'s Hospital (SNUCH), a 300-bed tertiary care university hospital and pediatric referral center located in Seoul, Korea.

Study population
----------------

From January 2000 through December 2009, we studied pediatric patients younger than 18 yr of age who had at least one positive blood culture for *P. aeruginosa* during hospitalization. The collected data included age, gender, type of acquisition, underlying disease, previous antimicrobial therapy, neutropenia, use of immunosuppressive treatment, prior surgery, use of vascular or urinary catheters, invasive procedures during the prior 72 hr, use of a mechanical ventilator within the previous month, presence of initial septic shock, respiratory difficulty, renal insufficiency, hepatic dysfunction, antibiotic susceptibility, MDR, and treatment outcome.

Definitions
-----------

The presence of *P. aeruginosa* bacteremia was defined as the isolation of *P. aeruginosa* in a blood culture ([@B12]). Only the first *P. aeruginosa* isolate, during a single clinical event, was included in the analysis. However, it was considered as a non-related, independent episode, if more than one episode was occurred with more than a two-week interval in a same patient who had been properly treated and clinically cured ([@B17]).

Septic shock was defined as sepsis and hypotension ([@B18]) (systolic blood pressure \[BP\] \< 70 mmHg in infant; \< 70 + \[2 × age in year\] after one year of age) or need for a vasopressor to maintain blood pressure ([@B12]). The primary focus of infection was defined as a culture-positive site and/or a clinically evident site of infection concomitant with bacteremia ([@B19]). Diagnosis of catheter-related bacteremia was defined as *P. aeruginosa* bacteremia in a patient who had an intravascular device and more than one positive blood culture result from the peripheral vein, clinical manifestations of infection (e.g., fever, chills, and/or hypotension), and no apparent source for BSI (with the exception of the catheter). One of the following should be present: a positive result of semiquantitative (\> 15 colony-forming unit per catheter segment) or differential time to positivity (growth in a culture of blood obtained through a catheter hub detected via an automated blood culture system at least 2 hr earlier than a culture of simultaneously drawn peripheral blood of equal volume) ([@B20]). Prior steroid use was defined as at least 2 mg/kg/day or ≥ 20 mg of prednisone daily for at least ten of the 30 days before the diagnosis of bacteremia. Patients who had malignant disease, premature babies, and patients receiving steroid therapy were classified as immunocompromised ([@B19]).

The empirical antimicrobial therapy was considered appropriate if the causative organism was susceptible to at least one of the prescribed antimicrobials according to an in vitro test within 24 hr after blood culture sampling ([@B12], [@B19]).

Microbiology and antibiotic susceptibility
------------------------------------------

*P. aeruginosa* isolates obtained from the blood of patients at the SNUCH during the study period from January 2000 through December 2009 were collected and stored at -70℃. Species identification was carried out using VITEK-GNI cards (BioMerieux, Hazelwood, MO, USA) from 2000 to 2006 and was performed using the VITEK II system (BioMerieux) or Microscan system (MicroScan® WalkAway 96 plus system, Siemens Healthcare Diagnostics Inc., West Sacramento, CA, USA) after 2006.

Antibiotic susceptibility testing was performed using the disk diffusion method recommended by the CLSI guidelines ([@B21]) or the automatically calculated minimal inhibitory concentration (MIC) method of VITEK or a Microscan system. The tested antibiotics included amikacin, aztreonam, cefepime, ceftazidime, ciprofloxacin, gentamicin, imipenem, piperacillin, piperacillin/tazobactam, and tobramycin. Intermediate susceptibility to an antibiotic was considered as resistance, in correspondence with clinical practice. MDR was defined as a lack of susceptibility to three or more of the following antibiotics: 1) ciprofloxacin; 2) imipenem; 3) gentamicin, tobramycin, or amikacin; 4) ceftazidime or cefepime; and 5) piperacillin or piperacillin-tazobactam ([@B22]).

Statistical analysis
--------------------

Potential risk factors for MDR *P. aeruginosa* bacteremia and mortality were identified using univariate analysis, and Fisher\'s exact test was used for categorical variables. Variables for which the *P* value was \< 0.05 in univariate analysis were included in a logistic regression model for multivariable analysis using a backward-Wald selection process. A *P* value \< 0.05 was considered statistically significant. A statistical package (SPSS, version 17.0, SPSS Inc, Chicago, IL, USA) was used for all analyses.

Ethics statement
----------------

This study was approved by the institutional review board of the Seoul National University Hospital (IRB registration number H-1007-151-324). Informed consent was exempted by the board.

RESULTS
=======

Epidemiology and demographic characteristics
--------------------------------------------

During the period from January 2000 to December 2009, a total of 75 patients with *P. aeruginosa* bacteremia were identified at the SNUCH. On average, 7.5 episodes of *P. aeruginosa* bacteremia occurred in one year with a range of 1-15 cases per year. The mean incidence rate (± standard deviation; SD) was 0.09 (± 0.05) episodes/1,000 patient-admission days per year. Among the 75 cases of *P. aeruginosa* bacteremia, medical records were unavailable for 13 (17.3%) patients, which were excluded from clinical analysis and as a result, a total of 62 episodes was analyzed in this study.

The mean (± SD) age of the patients was 6.5 (± 5.5) yr old (range; 0-17 yr old), and 40 (64.5%) patients were male ([Table 1](#T1){ref-type="table"}). *P. aeruginosa* bacteremia occurred in a mean of 29.5 hospital-days.

Fifty-nine (95.2%) of 62 patients had underlying disease. The most common underlying diseases were hematological and oncological disease; 58.1% (36/62) of the patients had neutropenia with an absolute neutrophil count \< 500 cells/µL at the onset of bacteremia. Three patients (4.8%) had no underlying disease, and all of these patients were younger than one year of age. The initial diagnoses in these three were pneumonia with pleural effusion, severe skin infection, and bacteremia without focus.

At the onset of bacteremia, 40 patients (64.5%) had infection foci. The most common infection site was the lung (22.6%; 14/62), followed by skin and soft tissue (16.1%; 10/62) and central catheter-related infection (11.3%; 7/62). Primary sites of infection could not be elucidated in 35.5% (22/62) cases.

Antimicrobial susceptibility
----------------------------

Of the 62 *P. aeruginosa* isolates, the resistance rates for the antibiotics were as follows; 24.2% for aztreonam, 16.1% for imipenem, 14.5% for gentamicin, 12.9% for piperacillin and piperacillin/tazobactam, and 11.3% for cefepime and ceftazidime, respectively.

Seven isolates (11.3%) showed MDR phenotypes, five of which were identified in 2003; remaining two isolates were identified in each year of 2005 and 2008, separately. For the MDR phenotypes, there was no overlapping patient. *P. aeruginosa* isolates with cefepime, piperacillin and piperacillin/tazobactam resistance showed MDR phenotypes substantially. Pan-drug resistance for *P. aeruginosa* was not yet identified in this study. Only one (1.6%) isolate was resistant against amikacin. All of the isolates tested were susceptible to ciprofloxacin.

Risk factors for MDR *P. aeruginosa* bacteremia
-----------------------------------------------

The variables considered as possible risk factors for acquisition of MDR-*P. aeruginosa* are shown in [Table 2](#T2){ref-type="table"}. In the univariate analysis, MDR-*P. aeruginosa* cases were more frequently associated with previous extended-spectrum cephalosporin use within one month (OR, 6.0; 95% CI, 1.2-31.1), an intensive care unit (ICU) stay (OR, 6.8; 95% CI, 1.3-35.8), and a long hospital stay (\> 30 days) (OR, 5.3; 95% CI, 1.0-27.4).

An ICU stay within the previous one month was the only statistically-significant risk factor for MDR acquisition in the multivariate analysis, adjusted for age and gender in addition to the variables with *P* \< 0.05 in the univariate analysis (adjusted OR, 6.8; 95% CI, 1.3-35.8, *P* = 0.023)

Clinical outcomes of *P. aeruginosa* bacteremia
-----------------------------------------------

The overall case fatality associated with *P. aeruginosa* bacteremia was 14.5% (9 of 62). The fatality rate of the MDR-*P. aeruginosa* group was 57.1% (4/7) compared with 9.1% (5/55) in the non-MDR group (OR, 13.3; 95% CI, 2.3-77.2, *P* = 0.006).

A higher fatality rate was observed in the cases with the following factors by the univariate analysis; pulmonary infection, presentation with septic shock, respiratory difficulty, renal insufficiency, and antibiogram of MDR phenotype ([Table 3](#T3){ref-type="table"}). Presence of respiratory difficulty was revealed to be an independent risk factor for higher all-cause fatality according to the multivariate logistic regression analysis adjusted for age, gender and the variables with *P* \< 0.05 in the univariate analysis (OR, 51.0; 95% CI, 7.0-369.0, *P* \< 0.001).

Nine (14.5%) patients were treated with inappropriate initial antimicrobial regimens for *P. aeruginosa* bacteremia; six (66.6%) of these patients did not receive any antibiotics directed against *P. aeruginosa* (e.g. anti-pseudomonal beta-lactams) as an initial empirical treatment. Three (33.3%) of the nine patients were initially treated with antibiotics that have known anti-pseudomonal activity, for which the isolates were actually resistant based on the in vitro susceptibility test. The fatality rate of the patients who were treated with appropriate initial antimicrobial regimens for *P. aeruginosa* bacteremia was 15% (8/53) and the fatality rate among the patients with inappropriate initial antimicrobial regimens was 11.1% (1/9); a statistically significant difference among these two groups was not observed (*P* = 0.755 by Fisher\'s exact test).

DISCUSSION
==========

The objective of the present retrospective study was to evaluate the clinical patterns, antibiotic sensitivity, independent risk factors for MDR and treatment outcomes of *P. aeruginosa* bacteremia in children. We found that fifty-nine (95.2%) of 62 patients had underlying disease, seven isolates (11.3%) showed MDR phenotypes, and overall case fatality was 14.5% (9 of 62). We also found that ICU stay within the previous one month was independently associated with the development of MDR *P. aeruginosa* bacteremia, and presentation with respiratory difficulty was an independent risk factor for all-cause fatality due to *P. aeruginosa* bacteremia. Previous investigations have already described risk factors of an MDR phenotype in *P. aeruginosa* infection. Cao et al. ([@B4]) demonstrated that the use of imipenem or meropenem and mechanical ventilation were independent risk factors for MDR *P. aeruginosa* infections. Johnson et al. ([@B22]) documented that previous transplantation, hospital-acquired BSI and ICU admission in the year before MDR *P. aeruginosa* BSI were independent risk factors. Gulay et al. ([@B23]) showed that the major risk factors for infection or colonization with MDR *P. aeruginosa* were prolonged stay in the ICU, previous and lengthy imipenem usage, and mechanical ventilation. To our knowledge, our study provides the first data revealing the risk factors of an MDR *P. aeruginosa* infections among pediatric groups based on the 10 yr observation, in which previous ICU stay was found to be a risk factor of MDR *P. aeruginosa* infection. It may be hypothesized that colonization of *P. aeruginosa* in the ICU can cause infection and may be a risk factor for MDR *P. aeruginosa* infection.

Recently, resistance to antimicrobial agents of *P. aeruginosa* has become a more serious clinical problem ([@B3], [@B24], [@B25]). Moreover, prevalence of MDR phenotype is increasing among *P. aeruginosa* in adult patients ([@B26], [@B27]). However, we were unable to demonstrate an increased imipenem-resistance or MDR phenotypes of *P. aeruginosa* bacteremia during the study period. This phenomenon might be associated with the small number of cases in this study. Furthermore, all isolates were susceptible to ciprofloxacin, which differs from results from another study ([@B28]). Recently the resistance rate for quinolone among *E. coli* and *K. pneumoniae* blood isolates obtained from children in our institute was increasing accompanying with an increment of quinolone usuage (unpublished data). As a result, continuous monitoring should be manditory for increasing trends of MDR phenotypes or quinolone resistance among *P. aeruginosa* isolates in pediatric hospitals.

Infections caused by MDR *P. aeruginosa* are difficult to treat ([@B4]). Our results show the case fatality for MDR group to be as high as 50% and higher than that in the non-MDR group, even though some studies have suggested that MDR phenotype is not a predictor for fatality with *P. aeruginosa* ([@B4], [@B22]). This fatality rate was consistent with the result of an earlier study which reported that the odds of death in patients with MDR *P. aeruginosa* bacteremia was 3.9 (95% CI, 1.42-10.78, *P* = 0.002) times higher than that for patients with non-MDR *P. aeruginosa* ([@B16]).

The fatality rate associated with *P. aeruginosa* bacteremia is higher than those of all other bacteremia in the hospital settings. Thus, appropriate initial antimicrobial therapy is of particular importance in these cases. There are several studies emphasizing the importance of appropriate initial antimicrobial treatment ([@B11], [@B12], [@B29]). Kang et al. ([@B12]) emphasized that delayed effective antimicrobial therapy for *P. aeruginosa* bacteremia, presentation with septic shock, pneumonia and increasing APACHE II score tended to be related to higher mortality. However, in another study, inactive empiric antibiotic therapy was not an independent predictor of mortality with MDR *P. aeruginosa* infection, but the authors postulated a small number of patients who received inappropriate empiric therapy (4.6%; 23/503) as the cause ([@B22]). In the current study, the initial appropriateness of antibiotics was not a predictor of fatality like a previous study ([@B22]). This result was probably due to the small number (14.5%) of the patients who had initially received inappropriate empirical therapy and who then later received the appropriate antibiotics.

In a pediatric study, Grisaru-Soen et al. ([@B14]) demonstrated that underlying disease was the only factor correlated with mortality according to multiple regression analysis. In our study, most of the *P. aueruginosa* bacteremia cases occurred to the patients with underlying disease, but underlying disease was not an independent risk factor (data was not shown). In our study, the presence of respiratory difficulty was the only independent risk factor related to overall fatality.

This study has several limitations. First, it was retrospective and performed at a single health-care center. Therefore, the results are not representative of all pediatric patients in Korea. Second, we did not conduct an analysis of the genotypes of the *P. aeruginosa* isolates and did not elucidate clustered occurrence of MDR phenotypes in 2003. Third, for the outcome analysis, the formal severity of the illness scores could not be calculated due to the retrospective nature of this study and to the absence of certain data in the medical records.

However, this study has some advantages. Our hospital is a referral institution and a university-affiliated tertiary hospital with relatively many pediatric patients diagnosed with *P. aeruginosa* bacteremia. In addition, this study included for invasive *P. aeruginosa* isolates obtained over a consecutive 10 yr.

In conclusion, our study revealed that a previous ICU stay was associated with acquisition of MDR *P. aeruginosa* and presentation with respiratory difficulty was independent predictors of fatal outcomes among pediatric patients with *P. aeruginosa* bacteremia. *P. aeruginosa* bacteremia has become a major concern not only for adults but also for children with underlying disease who are at high risk for health care-associated infection. Continuous monitoring is required for early detection of increment of MDR or PDR-phenotypes among *P. aeruginosa* isolates and for timely management of patients with probably higher fatality rate. Additionally, future efforts should be concentrated on the prevention and treatment of *P. aeruginosa* bacteremia in high-risk children.
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###### 

The characteristics of 62 patients with *P. aeruginosa* bacteremia
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^\*^These included leukemia (25.8%), solid tumor (24.2%), lymphoma (4.8%), hemophagocytic lymphoproliferative histiocytosis (4.8%), and aplastic anemia (3.2%).

###### 

Risk factors for MDR *P. aeruginosa* bacteremia in 62 patients from SNUCH over a ten-year period
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^\*^Variables with *P* \< 0.05 on univariate analysis were included in the multivariate analysis; ^†^Patients who had malignant disease, premature birth, or who had received steroid therapy ([@B19]).

###### 

Risk factors for fatal outcomes associated with *P. aeruginosa* bacteremia
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^\*^Variables with *P* \< 0.05 on univariate analysis were included in the multivariable analysis; ^†^A serum creatinine level of \> 2.0 mg/dL or a requirement for dialysis ([@B19]); ^‡^A serum bilirubin concentration of \> 2.5 mg/dL, increased aspartate aminotransferase level or alanine aminotransferase level more than twice the normal level ([@B19]); ^§^Change in consciousness level ([@B19]); ^∥^A partial arterial O~2~ pressure of \< 60 mmHg, a partial arterial CO~2~ pressure of \> 50 mmHg, or a need for ventilator assistance ([@B19]).
